Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QRFPR | Q96P65 | 3/20 | 0.41 |
| ▸ | NMT2 | O60551 | 3/20 | 0.39 |
| ▸ | NMT1 | P30419 | 3/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22223575 | 0.82 | EPHX1 (0.41) | NMT2NMT1OPRM1OPRD1HDAC1 | |
| SCHEMBL18785522 | 0.80 | NMT1 (0.39) | QRFPRNMT2NMT1 | |
| SCHEMBL20633487 | 0.78 | NMT1 (0.41) | QRFPRNMT2NMT1 | |
| SCHEMBL18760191 | 0.77 | NMT1 (0.44) | NMT2NMT1 | |
| SCHEMBL23840117 | 0.76 | NMT1 (0.40) | QRFPRNMT2NMT1OPRM1OPRD1 | |
| SCHEMBL18786235 | 0.75 | EPHX1 (0.40) | NMT2NMT1HDAC1 | |
| SCHEMBL18760195 | 0.74 | EPHX1 (0.42) | NMT2NMT1HDAC1 | |
| SCHEMBL20633489 | 0.73 | NMT1 (0.41) | QRFPRNMT2NMT1OPRM1OPRD1 | |
| SCHEMBL22053732 | 0.73 | ALDH1A1 (0.47) | SIRT1SIRT2CTSKHDAC1 | |
| SCHEMBL18888158 | 0.70 | NMT1 (0.38) | NMT2NMT1SIRT1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11529424-B2 | Synthetic bioconjugates | SYMIC HOLDINGS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20200222548-A1 | SYNTHETIC BIOCONJUGATES | SYMIC HOLDINGS, INC. | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11529424-B2 | Synthetic bioconjugates | COL14A1, COL1A1, COL2A1 | QRFPR 360/4885NMT2 711/4885NMT1 315/4885 |
| US-20200222548-A1 | SYNTHETIC BIOCONJUGATES | COL14A1, COL1A1, COL2A1 | QRFPR 360/4885NMT2 711/4885NMT1 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.